hoe 33342 and zd 6126
hoe 33342 has been researched along with zd 6126 in 5 studies
Research
Studies (5)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Burns, PN; Foster, FS; Goertz, DE; Kerbel, RS; Yu, JL | 1 |
| Rojiani, AM; Siemann, DW | 1 |
| Blakey, DC; Griffiths, JR; Howe, FA; Kalber, TL; McIntyre, DJ; Robinson, SP; Ryan, AJ; Waterton, JC; Whittaker, L | 1 |
| Griffiths, JR; Howe, FA; Robinson, SP; Ryan, AJ; Waterton, JC | 1 |
| Bastianutto, C; Busson, P; Liu, FF; Lo, KW; Mocanu, JD; Shi, W; Skliarenko, J; Yip, KW | 1 |
Other Studies
5 other study(ies) available for hoe 33342 and zd 6126
| Article | Year |
|---|---|
High-frequency Doppler ultrasound monitors the effects of antivascular therapy on tumor blood flow.
Topics: Angiogenesis Inhibitors; Animals; Benzimidazoles; Humans; Melanoma; Mice; Mice, Nude; Neovascularization, Pathologic; Organophosphorus Compounds; Staining and Labeling; Tumor Cells, Cultured; Ultrasonics; Ultrasonography; Xenograft Model Antitumor Assays | 2002 |
The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors.
Topics: Angiogenesis Inhibitors; Animals; Benzimidazoles; Drug Screening Assays, Antitumor; Fluorescent Dyes; Humans; Mice; Mice, Inbred C3H; Mice, Nude; Necrosis; Neoplasms; Neovascularization, Pathologic; Organophosphorus Compounds; Sarcoma; Transplantation, Heterologous | 2005 |
Acute tumor response to ZD6126 assessed by intrinsic susceptibility magnetic resonance imaging.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Female; Hemoglobins; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Microscopy, Fluorescence; Neoplasms; Organophosphorus Compounds; Perfusion; Prognosis; Prolactinoma; Rats; Rats, Wistar; Time Factors | 2005 |
Susceptibility contrast magnetic resonance imaging determination of fractional tumor blood volume: a noninvasive imaging biomarker of response to the vascular disrupting agent ZD6126.
Topics: Animals; Benzimidazoles; Blood Volume; Contrast Media; Dextrans; Female; Ferrosoferric Oxide; Fluorescent Dyes; Iron; Magnetic Resonance Imaging; Magnetite Nanoparticles; Organophosphorus Compounds; Oxides; Pituitary Neoplasms; Prolactinoma; Rats | 2007 |
Imaging and modulating antisense microdistribution in solid human xenograft tumor models.
Topics: Algorithms; Animals; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Diagnostic Imaging; Humans; Hypoxia; Mice; Mice, SCID; Necrosis; Neoplasm Transplantation; Oligonucleotides, Antisense; Organophosphorus Compounds; Xenograft Model Antitumor Assays | 2007 |